RSV Vaccine Safety Confirmed in Seniors

Aug 1, 2026 · Published in: Drug Safety

Background Information

Two years of data confirm broader safety for RSV vaccine in seniors.

A comprehensive safety review of the AS01E-adjuvanted RSVPreF3 vaccine provides critical insights for healthcare providers managing older adult patients. Of 13.4 million doses distributed, 7012 adverse events were reported, mostly non-serious; no increased risk of Guillain-Barré syndrome was observed. Findings support the favorable safety profile of the vaccine, important for informed decision-making in the elderly population regarding vaccine use. Post-marketing data reinforce the safety of AS01E-adjuvanted RSVPreF3 in older adults.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Tregunno C, Deraedt Q, Cuadripani S, Verheust C, Bryan P

Citation: Tregunno C, Deraedt Q, Cuadripani S, et al. AS01(E)-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine (Adjuvanted RSVPreF3): Review of the First 2 Years of Post-Marketing Safety Surveillance. Drug safety. 2026. doi:10.1007/s40264-026-01698-y

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

Deep Analysis Pending

The full analysis for this article is being written and reviewed. Every analysis is checked by a licensed pharmacist before it publishes.